Symbols

VRTX

Vertex Pharmaceuticals·NASDAQ

--(--)

VRTX fundamentals

VRTX Q4 2025 Earnings

Vertex Pharmaceuticals (VRTX) released its earnings on Feb 12, 2026: revenue was 3.19B (YoY +9.55%), beat estimates; EPS was 5.03 (YoY +26.38%), missed estimates.

Revenue / YoY

3.19B

+9.55%

EPS / YoY

5.03

+26.38%

Report date

Feb 12, 2026

VRTX Earnings Call Summary for Q4,2025

Revenue Growth: 10% Q4 and 9% full-year growth, driven by CF and new products.
ALYFTREK Breakthrough: 65% of young CF patients achieved normal sweat chloride levels.
Pove Potential: Phase III interim analysis expected in 2026 with 56% proteinuria reduction in Phase II.
JOURNAVX Momentum: 76% opioid-free surgical patients, prescriptions to triple in 2026.
2026 Outlook: $12.95-13.1B revenue target, >$500M non-CF contribution.

Earnings

EPS

Revenue

Revenue & Expenses

VRTX has released its 2025 Q4 earnings report, with revenue of 3.19B, reflecting a YoY change of 9.55%, and net profit of 1.19B, showing a YoY change of 30.46%. The Sankey diagram below clearly presents VRTX's revenue sources and cost distribution.

Key Indicators

Vertex Pharmaceuticals (VRTX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Vertex Pharmaceuticals (VRTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Vertex Pharmaceuticals (VRTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Vertex Pharmaceuticals (VRTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown